Achilles Therapeutics plc
NASDAQ: ACHL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Iraj Ali
- Employees
- 204
- Headquarters
- London, United Kingdom
- IPO year
- 2021
- Market cap
- $60.8M
- Website
- https://www.achillestx.com
Loading ACHL…
Loading profile data…Frequently asked questions about ACHL
What does Achilles Therapeutics plc (ACHL) do?
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small c...
Where does ACHL trade?
Achilles Therapeutics plc (ACHL) trades on the NASDAQ Global Select.
What sector is ACHL in?
Achilles Therapeutics plc (ACHL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Achilles Therapeutics plc?
Iraj Ali is the chief executive officer of Achilles Therapeutics plc (ACHL).
Where is Achilles Therapeutics plc headquartered?
Achilles Therapeutics plc is headquartered in United Kingdom.
Does ACHL pay a dividend?
Achilles Therapeutics plc (ACHL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ACHL go public?
Achilles Therapeutics plc (ACHL) completed its initial public offering in 2021.
Is ACHL an ADR?
Yes — ACHL is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Achilles Therapeutics plc reporting and dividends follow the underlying issuer.